BIOREGENX, INC.
Data quality: 100%
BRGX
OTC
Technology
IT Services
$0.01
$0.00
(0.00%)
Mkt Cap: 11.44 M
Price
$0.01
Mkt Cap
11.44 M
Day Range
$0.01 — $0.01
52-Week Range
$0.01 — $0.03
Volume
9,339
Open $0.01
50D / 200D Avg
$0.01
9.16% below
50D / 200D Avg
$0.01
12.50% below
Quick Summary
Key Takeaways
Negative free cash flow of -48,025.0
Capital efficient — spends only 0.31% of revenue on capex
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)10420.64%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
N/A
ROICN/A
Net Margin-980.96%
Op. Margin-965.35%
Safety
Debt / Equity
N/A
Current Ratio0.07
Interest Coverage-116.53
Valuation
PE (TTM)
-0.60
Below sector avg (-0.16)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Technology sector median (1060 peers)
Peer Comparison
vs Technology sector median (1060 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -0.6 | -0.2 |
| P/B | — | 3.0 |
| ROE % | — | 1.7 |
| Net Margin % | -981.0 | -0.5 |
| Rev Growth 5Y % | — | 7.3 |
| D/E | — | 0.4 |
Analyst Price Target
No analyst coverage available
Earnings Estimates
No forward estimates available
No quarterly estimates available
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 10420.64% | Revenue Growth (3Y) | 645.03% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 1.93 M | Net Income (TTM) | -18.93 M |
| ROE | N/A | ROA | -1632.76% |
| Gross Margin | 78.14% | Operating Margin | -965.35% |
| Net Margin | -980.96% | Free Cash Flow (TTM) | -48,025.0 |
| ROIC | N/A | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 0.07 |
| Interest Coverage | -116.53 | Asset Turnover | 1.66 |
| Working Capital | -3.66 M | Tangible Book Value | -4.37 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0.60 | Forward P/E | N/A |
| P/B Ratio | N/A | P/S Ratio | 5.93 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -0.42% | ||
| Market Cap | 11.44 M | Enterprise Value | 11.44 M |
| Per Share | |||
| EPS (Diluted TTM) | -0.01 | Revenue / Share | 0.00 |
| FCF / Share | 0.00 | OCF / Share | 0.00 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 0.31% | FCF Conversion | 0.25% |
| SBC-Adj. FCF | -1.54 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | 2.34 M | 22,243.0 | 42,159.0 |
| Net Income | -23.05 M | -571,171.0 | -78,308.0 |
| EPS (Diluted) | -0.02 | 0.00 | 0.00 |
| Gross Profit | 1.66 M | — | 42,159.0 |
| Operating Income | -22.76 M | -109,663.0 | -78,308.0 |
| EBITDA | — | — | — |
| R&D Expenses | 0.0 | — | — |
| SG&A Expenses | 5.85 M | — | — |
| D&A | 2.22 M | — | — |
| Interest Expense | 6,638.0 | 8,276.0 | — |
| Income Tax | — | 0.0 | 0.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Total Assets | 508,535.0 | 31,640.0 | 59,149.0 |
| Total Liabilities | 3.89 M | 253,612.0 | 260,691.0 |
| Shareholders' Equity | -3.38 M | -221,972.0 | -201,542.0 |
| Total Debt | 1.14 M | 200,000.0 | 200,000.0 |
| Cash & Equivalents | 58,404.0 | — | — |
| Current Assets | 307,796.0 | 0.0 | 676.0 |
| Current Liabilities | 3.63 M | 253,612.0 | 64,880.0 |
{"event":"ticker_viewed","properties":{"ticker":"BRGX","listing_kind":"stock","pathname":"/stocks/brgx","exchange":"OTC","country":"US"}}